International Orthopaedic company Maxx Medical, Pvt. Ltd., has announced that its award-winning Freedom Total Knee® System (“Freedom Knee”) has recently received Chinese State Food and Drug Administration (SFDA) approval and will shortly be available throughout the country.
Freedom Knee is a complete, high-flexion primary knee replacement system specifically engineered to address what Maxx Medical claims is an unmet market need for smaller sized and differently proportioned implants that better support Asian lifestyle and physiology.
Maxx Medical says its Freedom Knee leverages advanced engineering technologies and deep clinical expertise to enhance every aspect of total knee replacement surgery, including surgical technique, instruments and implants. Known as the “Asian Knee,”
The company claims the Freedom Knee is the only system sold globally, yet designed with features that specifically address Asian patients’ needs, including:
- Size & Fit — Freedom Knee offers innovative implant components, including smaller and transitional sizing options, so that surgeons can better customise fit according to patient size and stature.
- High Flexion — Freedom Knee supports the deep knee bending and range of motion needs of Asian patients, and features the only known all-poly tibial component specifically designed for high flexion and approved by the US FDA.
- Bone Preservation — Freedom Knee enables surgeons to preserve more bone stock, which better supports patients’ long-term mobility. In some cases, surgeons are able to conserve 50 percent more bone stock than with other contemporary systems. This is especially important for Asian patients who tend to have less bone stock than their western counterparts.
“We’re excited to bring the benefits of Freedom Knee to surgeons and patients throughout China. There was a need for new joint replacement solutions developed to accommodate population-specific nuances, particularly in Asia, where retro-fit western implant systems were the only options,” said Ashesh Shah, CEO, Maxx Medical. “We’ve already seen the dramatically improved mobility in patients throughout the Middle East and South Asia that Freedom Knee has enabled, and are confident that Chinese patients suffering from knee pain will equally benefit.”
Launched in 2009, Freedom Knee recently received leading analyst group Frost & Sullivan’s “Product Differentiation Excellence Award in Orthopedic Knee Joint Replacement.” In addition to SFDA approval, Freedom Knee has US FDA, Drugs Controller General of India (DCGI) and European CE Mark approvals. Freedom Knee is manufactured in the United States.
Maxx Medical is actively seeking distributors to support the launch of Freedom Knee in China. It is inviting interested parties to make contact via its website.
Source: Maxx Medical, PR Web